The Korean Journal of Hematology最新文献

{"title":"The prevalence of anemia and iron depletion in the population aged 10 years or older.","authors":"Soon Ki Kim,&nbsp;Hee Sook Kang,&nbsp;Chul Soo Kim,&nbsp;Young Taek Kim","doi":"10.5045/kjh.2011.46.3.196","DOIUrl":"https://doi.org/10.5045/kjh.2011.46.3.196","url":null,"abstract":"<p><strong>Background: </strong>Anemia and iron depletion continue to be common disorders in the world. This study was aimed at assessing the prevalence of anemia and iron depletion in apparently healthy Koreans aged 10 years or more.</p><p><strong>Methods: </strong>We used the data of the 4(th) Korean National Health & Nutrition Examination Survey (KNHANES), which assessed 7,607 individuals (3,337 males and 4,270 females). Iron depletion was defined as serum ferritin less than 15 ng/mL.</p><p><strong>Results: </strong>In males, mean hemoglobin (Hb) concentration decreased after the age of 50. The prevalence of anemia was 7.1% in 60 to 69 year olds and 12.3% in men aged 70 or older. As for females, the prevalence of anemia was 8.8% in 15 to 17 year olds, 16.7% in 18 to 49 year olds, 10.9% in 60 to 69 year olds, and 18.2% women aged 70 or older. In males, the prevalence of iron depletion was 8.6% at ages 10 to 14 years, 3.9% at 15 to 17, and 2.6% at 70 years or older. In females, the prevalence of iron depletion was 17.2% at ages 10 to 14 years, 24.1% at 15 to 17, 33.0% at 18 to 49, and 5.7% at 70 years or older. Although normocytic anemia was most common in both males and females, the proportion of microcytosis and macrocytosis increased at age 70 or older.</p><p><strong>Conclusion: </strong>The prevalence of anemia and iron depletion was high in women of reproductive age and in the elderly. Considering the rapid increase in the older population, an intervention to prevent anemia and iron depletion is imperative.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"46 3","pages":"196-9"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2011.46.3.196","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40137509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of follicular B-cell lymphoma treated using clarithromycin.","authors":"Masashi Ohe,&nbsp;Satoshi Hashino","doi":"10.5045/kjh.2011.46.3.203","DOIUrl":"https://doi.org/10.5045/kjh.2011.46.3.203","url":null,"abstract":"<p><p>We report a case of follicular B-cell lymphoma (FL) treated successfully using clarithromycin (CAM). A 44-year-old man who presented with lymphadenopathy was diagnosed with FL after a histological examination of his biopsy specimens. He was administered chemotherapy with R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone) following which stable disease was achieved. However, the subsequent clinical course showed partial remission of FL and stable disease with tumor regrowth, each of which was treated with chemotherapeutic regimens. Since the patient was diagnosed with leukocytopenia, he could not undergo chemotherapy for the third regrowth; hence, he was administered CAM. His lymphadenopathy regressed and the levels of soluble interleukin 2-receptor decreased. This case shows that treatment using CAM may be effective in some cases of FL.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"46 3","pages":"203-6"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2011.46.3.203","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40137511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma cell leukemia with rouleaux formation involving neoplastic cells and RBC.","authors":"Sung Ran Cho","doi":"10.5045/kjh.2011.46.3.152","DOIUrl":"https://doi.org/10.5045/kjh.2011.46.3.152","url":null,"abstract":"which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. A 77-year-old man visited our hospital complaining of fever, excessive sputum production, and dyspnea. immature plasma cells (plasmablasts), accounting for 58% of the leukocytes, and marked rouleaux formation (A). Interestingly, rouleaux formation of the neoplastic cells was also noted (B). Bone marrow study showed plasmablasts, accounting for 93% of all nucleated cells. Serum protein electrophoresis and immunotyping revealed a monoclonal peak of IgG and lambda light chain type. The amount of M-protein was 6.0 g/dL. High-resolution computed tomo-graphy of both lungs revealed multifocal consolidations with fuzzy marginated centrilobular pattern nodules, which were consistent with the findings in multifocal bronchopneumonia. Plasma cell leukemia is a variant of plasma cell myeloma with clonal plasma cell numbers in peripheral blood exceeding 2.0×10 9 /L or 20% of the leukocyte differential count. Rouleaux formation, involving the stacking of RBCs upon one another so that they resemble a stack of coins, is particularly marked in paraproteinemia. The patient showed a rouleaux formation involving not only RBCs but also neoplastic cells.","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"46 3","pages":"152"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2011.46.3.152","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40138103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABO-incompatible renal transplantation: From saline flushes to antigen-specific immunoadsorption-Tools to overcome the barrier.","authors":"Mario Schiffer,&nbsp;Jan T Kielstein","doi":"10.5045/kjh.2011.46.3.164","DOIUrl":"https://doi.org/10.5045/kjh.2011.46.3.164","url":null,"abstract":"<p><p>On April 23, 1951, a 30-year-old woman received the first intentional ABOi (ABO incompatible) renal transplantation in Boston. At that time, it was commonly believed that intensely rinsing the graft to remove blood would be sufficient to overcome any immunological problems associated with blood type incompatibility. However, when the abovementioned patient and another ABOi transplant recipient died within a month, Humes and colleagues arrived at the same conclusion: \"We do not feel that renal transplantation in the presence of blood incompatibility is wise.\" In the decades that followed, we learned that the oligosaccharide surface antigens representing the ABO-blood group antigens are expressed not only on erythrocytes but also on cells from various tissues, including the vascular endothelium. The growing gap between organ demand and availability has sparked efforts to overcome the ABO barrier. After its disappointing results in the early 1970s, Japan became the leader of this endeavor in the 1980s. All protocols are based on 2 strategies: removal of preformed antibodies with extracorporeal techniques and inhibition of ongoing antibody production. Successful ABOi renal transplantation became possible with the advent of splenectomy, new immunosuppressive drugs (e.g., rituximab, a monoclonal antibody against CD20), and extracorporeal methods such as antigen-specific immunoadsorption. This review summarizes the underlying pathophysiology of ABOi transplantation and the different protocols available. Further, we briefly touch potential short- and long-term problems, particularly the incidence of infectious complications and malignancies, that can arise with high-intensity immunosuppressive therapy.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"46 3","pages":"164-8"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2011.46.3.164","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40138105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent® Technology.","authors":"Takefumi Matsushita","doi":"10.5045/kjh.2011.46.3.148","DOIUrl":"https://doi.org/10.5045/kjh.2011.46.3.148","url":null,"abstract":"With more than 30 therapeutic antibodies approved worldwide, therapeutic antibodies have become a major category in the pharmaceutical market. In an effort to further expand the potential of therapeutic antibodies, several approaches are being employed, such as improving the effector functions of the antibodies, designing antibody-drug conjugates, and downsizing the antibody molecule. Among these approaches, enhancing antibody-dependent cellular cytotoxicity (ADCC), which is the major effector function of an antibody, is thought to be one of the most promising and practical approaches to make an antibody more efficacious. In this \"Perspective\", we have provided an overview of such ADCC-enhancing technologies, while focusing mainly on our Potelligent® Technology, which has been most extensively tested in clinical trials.","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"46 3","pages":"148-50"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2011.46.3.148","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40138101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of anti-mitochondrial antibodies in a patient with chronic graft-versus-host disease following hematopoietic stem cell transplantation.","authors":"Dong Hyun Lee,&nbsp;Seok Jae Huh,&nbsp;Hyun Hwa Yoon,&nbsp;Sung Woo Lee,&nbsp;Kyeong Hee Kim,&nbsp;Sung-Hyun Kim","doi":"10.5045/kjh.2011.46.3.200","DOIUrl":"https://doi.org/10.5045/kjh.2011.46.3.200","url":null,"abstract":"<p><p>Recent studies indicate that patients with chronic graft-versus-host disease (GVHD) are not expected to show positivity for anti-mitochondrial antibody (AMA), which is a specific disease marker for primary biliary cirrhosis (PBC). A differential diagnosis between PBC and hepatic involvement of GVHD based on clinical manifestations and pathologic study is difficult because both diseases show similar results. Therefore, the presence of AMA may be important for distinguishing each disease. Here, we report a case of hepatic involvement of chronic GVHD with positive AMA, in which the pathologic findings and initial presentation of clinical findings were compatible with both PBC and chronic GVHD.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"46 3","pages":"200-2"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2011.46.3.200","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40137510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A controversial conclusion regarding primary extranodal diffuse large B-cell lymphoma.","authors":"Seong Kyu Park,&nbsp;Jina Yun,&nbsp;Se Hyung Kim,&nbsp;Dae Sik Hong","doi":"10.5045/kjh.2011.46.3.207","DOIUrl":"https://doi.org/10.5045/kjh.2011.46.3.207","url":null,"abstract":"TO THE EDITOR: \u0000 \u0000Recently, primary extranodal non-Hodgkin's lymphoma (NHL) has gained considerable attention. Many controversies are associated with primary extranodal NHL, mainly due to inadequate and contradictory literatures, and lack of uniformity in definition, clinicopathological characteristics, and clinical outcomes according to the involved sites. Jang et al. put forth prospects for further research to evaluate primary extranodal DLBCL [1]. Although they concluded that rituximab had no role in the treatment of primary extranodal DLBCL, their report included several limitations that were obstacles to achieve conclusive results. \u0000 \u0000The diversity in clinical presentation, morphology, immunophenotype, and genetic alterations strongly suggest that DLBCL belongs to a heterogeneous group of aggressive B-cell lymphomas. Extranodal disease is the predominant disease manifestation (incidence, about 40%) among DLBCL patients. Even in patients with stage I disease, 56% had extranodal DLBCL [2]. On the basis of the results of routine staging, the authors defined PENL (primary extranodal lymphoma) as a lymphoma with no or minor nodal involvement, along with a clinically dominant extranodal component. The definition of extranodal disease has been controversial, particularly in the presence of both nodal and extranodal manifestations. The designation of stage III and IV lymphomas as PENLs is debatable, since many clinicians consider only stage I and II presentations as primary extranodal disease [3]. For patients in the advanced stage of disease, this diagnostic approach may be inappropriate, because many extranodal lymphomas can disseminate and vice versa. In the above study, patients with stage III or IV disease constituted more than 50% of all subjects. Therefore, this definition for PENL inevitably introduces a selection bias. \u0000 \u0000The second controversial issue is the different prognosis according to the involved site. Lopez-Guillermo et al. [4] reported that the clinical characteristics of nodal and extranodal DLBCLs were heterogeneous. Lymphomas arising from two specific sites [Waldeyer's ring (nodal) and gastrointestinal region (extranodal)] showed very favorable characteristics at diagnosis (e.g., early stage, absence of bone marrow involvement, normal serum LDH level, and low-risk IPI), whereas DLBCLs arising in the remaining areas (lymph nodes or other extranodal sites) presented with poorer diagnostic characteristics. In terms of response to therapy, risk of relapse and overall survival, both Waldeyer's ring and gastrointestinal lymphomas showed notably better outcomes than those shown by the other groups [4, 5]. Thus, not only the nodal or extranodal presentation, but also involvement of specific sites may be related to particular clinicobiological characteristics and disease outcomes. The authors did not provide detailed information about the involved sites and differences in patient's characteristics between the extranodal and nodal diseas","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"46 3","pages":"207-8"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2011.46.3.207","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40137512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-grade lymphoma: Beyond fludarabine-single therapy.","authors":"Eunkyung Park","doi":"10.5045/kjh.2011.46.3.145","DOIUrl":"https://doi.org/10.5045/kjh.2011.46.3.145","url":null,"abstract":"Most patients with low-grade non-Hodgkin's lymphoma (NHL) present with disseminated disease, although many are asymptomatic at diagnosis. Several initial approaches have been used to treat such patients, but none of the treatment options have resulted in long-term disease-free survival in majority of these patients. Although some patients may achieve complete remission (CR), the remission is short-lived and usually followed by a relapse. Therefore, the prognosis for patients with indolent lymphoma (median survival, 8-10 years) has not improved much over time [1]. However, recent survival data for patients with advanced indolent lymphoma suggest that the overall survival (OS) rate has improved over the last 25 years, probably because of sequential application of different chemotherapy regimens, use of biologic agents, and improved supportive care. \u0000 \u0000Conventional therapy for low-grade NHL involves monotherapy with an alkylating agent (chlorambucil or cyclophosphamide) or administration of alkylating agents in combination with or without anthracyclines (cyclophosphamide, vincristine, and prednisone or cyclophosphamide, vincristine, prednisone, and doxorubicin), depending on the clinical aggressiveness of the disease. The unsatisfactory results observed in terms of CR and long-term disease control led to the therapeutic investigation of purine analogues in this disease subset. \u0000 \u0000The past decade has witnessed the emergence of fludarabine as an active agent for low-grade NHL treatment. Although early trials with single-agent fludarabine showed response rates of 30-50% in previously treated patients, recent efforts have focused on combining fludarabine with other agents, especially mitoxantrone [2, 3] and cyclophosphamide [4]. Clinical trials with these combination regimens have reproducibly yielded overall response rates of 60-90% [5]. \u0000 \u0000The use of fludarabine, mitoxantrone, and dexamethasone (FND) induced a response rate of 94%, with a CR rate of 46% (duration of CR [median], 21 months). Although FND was well tolerated, many patients developed myelosuppression and opportunistic infections including Pneumocystis carinii, herpes zoster, and mycobacterial infections. The potent antilymphocytic activity of fludarabine, particularly for T cells, has been incriminated for this effect. Similar toxicities were reported in chronic lymphocytic leukemia (CLL) patients treated with fludarabine: addition of corticosteroids increased opportunistic infections without inducing significant antitumor effects. \u0000 \u0000The fludarabine and cyclophosphamide (FC) combination has been extensively studied for the management of CLL patients. FC was used as the first-line treatment and was associated with high rates of objective response (86-100%) and CR (20-60%). These results have been recently confirmed by 3 phase III studies, in which FC was compared with fludarabine and chlorambucil. The major toxicity in these studies was hematological: grade IV neutropenia associated with ","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"46 3","pages":"145-7"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2011.46.3.145","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40138100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fortuitous detection of esophageal pneumatosis in a neutropenic patient.","authors":"Seung-Ah Yahng,&nbsp;Hee-Je Kim","doi":"10.5045/kjh.2011.46.3.151","DOIUrl":"https://doi.org/10.5045/kjh.2011.46.3.151","url":null,"abstract":"which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. A 62-year-old woman with relapsed acute myeloid leukemia occurring 181 days after autologous stem-cell transplantation underwent reinduction chemotherapy as per the FLANG regimen (fludarabine 30 mg/m 2 /day, cytosine arabinoside 1 g/m 2 /day, mitoxantrone 10 mg/m 2 /day, and granulocyte colony-stimulating factor 300 μg/day for 5 days). On post-chemotherapy day 5, neutropenic fever developed and empirical antibiotic therapy was prescribed. Chest radiography performed 3 days later revealed several patchy consolidations on both lung fields. Physical examination yielded unremarkable results, except mild oral mucositis. Serum galactomannan assay was elevated (＞6.4). Chest computed tomography (CT) showed multifocal, patchy consolidations with surrounding ground-glass opacities in both lung parenchyma and infiltration along the bronchial trees (A). Further, we detected esophageal wall thickening with intramuscular air bubbles in the upper esophagus but sparing gastric and lower intestinal walls, indicating esophageal pneumatosis (B, C arrow). Since the patient reported no associated symptoms, no active treatment was considered other than total parenteral nutrition while amphoteric was added. Follow-up chest CT 14 days later revealed regression of pneumatosis but progression of pneumonia with cavity formation. Despite intensive management with daily donor granulocyte transfusions and mechanical ventilation, the patient died of progressive acute respiratory distress syndrome on post-chemotherapy day 43.","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"46 3","pages":"151"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2011.46.3.151","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40138102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","authors":"Jin Seok Kim,&nbsp;Soo-Jeong Kim,&nbsp;June-Won Cheong,&nbsp;Yundeok Kim,&nbsp;Doh Yu Hwang,&nbsp;Sulhee Yoon,&nbsp;Jieun Jang,&nbsp;Shin Young Hyun,&nbsp;Yoo Hong Min","doi":"10.5045/kjh.2011.46.3.175","DOIUrl":"https://doi.org/10.5045/kjh.2011.46.3.175","url":null,"abstract":"<p><strong>Background: </strong>BAFF (B cell-activating factor) and APRIL (a proliferation-inducing ligand) are members of the tumor necrosis factor family and promote B cell survival and proliferation. We evaluated the correlation between serum concentration of BAFF or APRIL and severity of acute graft-versus-host disease (GVHD).</p><p><strong>Methods: </strong>Fifteen patients who received allogeneic hematopoietic stem transplantation for leukemia and developed acute GVHD were enrolled. We determined serum concentrations of BAFF and APRIL at the onset of the first clinical manifestation of GVHD by enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>Nine patients had grade 2 acute GVHD, and 6 had grade 3-4 acute GVHD. The BAFF serum concentration was higher in patients with grade 3-4 acute GVHD (1,093.42 in grade 2 vs. 2,171.99 pg/mL in grade 3-4), although the difference was not significant (P=0.077). However, the ratio of BAFF serum concentration to absolute lymphocyte count (ALC) (BAFF/ALC) was significantly higher in patients with grade 3-4 acute GVHD (P=0.045). The APRIL serum concentration and APRIL/ALC ratio showed similar results (P=0.077 and P=0.013, respectively).</p><p><strong>Conclusion: </strong>Patients with grade 3-4 acute GVHD had higher BAFF/ALC and APRIL/ALC ratios than patients with grade 2 acute GVHD. These findings suggest that B cells might play an important role in the development of acute GVHD, and that the BAFF and APRIL concentrations in serum might be significant predictive factors for estimating the severity of acute GVHD. Their clinical significance should be further evaluated in a larger patient population.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"46 3","pages":"175-9"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2011.46.3.175","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40138107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}